Predictive factors for an uncomplicated long-term course of Crohn's disease: A retrospective analysis

Journal of Crohn's and Colitis

Volumn 7, Issue 7, 2013, Pages

  Kruis, W ^a   Katalinic, A ^b   Klugmann, T ^c   Franke, G R ^d   Weismuller J ^e   Leifeld, L ^a   Ceplis Kastner, S ^f   Reimers, B ^f   Bokemeyer, B ^g,h  

^a Evangelisches Krankenhaus Kalk   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c Internistische Gemeinschaftspraxis   (Germany)

^d Ärztehaus Südhang ^*  (Germany)

^e Gastroenterologische Gemeinschaftspraxis   (Germany)

^f Ferring Arzneimittel GmbH   (Germany)

^g KLINIKUM MINDEN   (Germany)

^h UNIVERSITY OF KIEL   (Germany)

Author keywords

Clinical course; Crohn's; Mesalazine; Mild; Predictive score

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; MESALAZINE; PREDNISONE;

ADULT; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; FEMALE; FEVER; FISTULA; FOLLOW UP; HEALTH CARE COST; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT DURATION; TREATMENT FAILURE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHI-SQUARE DISTRIBUTION; CROHN DISEASE; FEMALE; HUMANS; INCIDENCE; MALE; MESALAMINE; PREDICTIVE VALUE OF TESTS; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84878650860     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.10.012     Document Type: Article

References (36)

1. Henriksen M., Jahnsen J., Lygren I., Aadland E., Schulz T., Vatn M.H., et al. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol 2007, 42:602-610. Ibsen Study Group.
2. Wolters F.L., Russel M.G., Sijbrandij J., Ambergen T., Odes S., Riis L., et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006, 55:1124-1130.
3. Gollop J.H., Phillips S.F., Melton L.J., Zinsmeister A.R. Epidemiologic aspects of Crohn's disease: a population based study in Olmsted County, Minnesota, 1943-1982. Gut 1988, 29:49-56.
4. Faubion W.A., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255-260.
5. Beaugerie L., Seksik P., Nion-Larmurier I., Gendre J.-P., Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006, 130:650-656.
6. D'Haens G., Baert F., van Assche G., Caenepeel P., Vergauwe P., Tuynman H., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
7. Cullen G., Keegan D., Mulcahy H.E., O'Donoghue D.P. A 5-year prospective observational study of the outcomes of international treatment guidelines for Crohn's disease. Clin Gastroenterol Hepatol 2009, 7:323-328.
8. Dignass A., Van Assche G., Lindsay J.O., Lémann M., Söderholm J., Colombel J.F., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010, 4:28-62. European Crohn's and Colitis Organisation (ECCO).
9. Bokemeyer B., Hartmann P., Kamp U., Roggel C. Morbus Crohn Patienten in der gastroenterologischen Fachpraxis- gibt es den leichten auf 5-ASA ansprechenden Verlauf? 2006, DGVS, Abstract P456.
10. Romberg-Camps M.J., Dagnelie P.C., Kester A.D., Hesselink-van de Kruijs M.A., Cilissen M., Engels L.G., et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 2009, 104:371-383.
11. Louis E., Belaiche J., Reenaers C. Do clinical factors help to predict disease course in inflammatory bowel disease?. World J Gastroenterol 2010, 16:2600-2603.
12. Allez M., Lémann M. Role of endoscopy in predicting the disease course in inflammatory bowel disease. World J Gastroenterol 2010, 16:2626-2632.
13. Schreiber S., Nikolaus S., Hampe J., Hämling J., Koop I., Groessner B., et al. Tumour necrosis factor alpha and interleukin 1 beta in relapse of Crohn's disease. Lancet 1999, 353:459-461.
14. Reinisch W., Gasche C., Tillinger W., Wyatt J., Lichtenberger C., Willheim M., et al. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol 1999, 94:2156-2164.
15. Louis E., Belaiche J., Van Kemseke C., Schaaf N., Mahieu P., Mary J.Y. Soluble interleukin-2 receptor in Crohn's disease. Assessment of disease activity and prediction of relapse. Dig Dis Sci 1995, 40:1750-1756.
16. Consigny Y., Modigliani R., Colombel J.F., Dupas J.L., Lémann M., Mary J.Y. A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis 2006, 12:551-557. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
17. Hoffmann J.C., Preiss J.C., Autschbach F., Buhr H.J., Häuser W., Herrlinger K., et al. Clinical practice guideline on diagnosis and treatment of Crohn's disease. Z Gastroenterol 2008, 46:1094-1146. [German].
18. Rutgeerts P., Geboes K., Vantrappen G., Beyls J., Kerremans R., Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990, 99:956-963.
19. Ott C., Takses A., Strauch U., Schölmerich J., Obermeier F. Factors influencing the use of immunomodulatory therapies during the early course of disease in patients with IBD - results of a population-based cohort. Gastroenterology 2009, 136(5 Suppl 1):A359.
20. Silverstein M.D., Loftus E.V., Sandborn W.J., Tremaine W.J., Feagan B.G., Nietert P.J., et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999, 117:49-57.
21. Munkholm P., Langholz E., Davidsen M., Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995, 30:699-706.
22. Cosnes J., Cattan S., Blain A., Beaugerie L., Carbonnel F., Parc R., et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002, 8:244-250.
23. Duricova D., Pedersen N., Elkjaer M., Jensen J.K., Munkholm P. 5-Aminosalicylic acid dependency in Crohn's disease: a Danish Crohn Colitis Database study. J Crohns Colitis 2010, 4:575-581.
24. Pigneur B., Seksik P., Viola S., Viala J., Beaugerie L., Girardet J.P., et al. Natural history of Crohn's disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis 2010, 16:953-961.
25. Koelewijn C.L., Schwartz M.P., Samsom M., Oldenburg B. C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J Gastroenterol 2008, 14:85-89.
26. Henriksen M., Jahnsen J., Lygren I., Stray N., Sauar J., Vatn M.H., et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008, 57:1518-1523. Ibsen Study Group.
27. Vermeire S., Van Assche G., Rutgeerts P. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2005, 2:580-586.
28. Mendoza J.L., Abreu M.T. Biological markers in inflammatory bowel disease: practical consideration for clinicians. Gastroenterol Clin Biol 2009, 33(Suppl. 3):S158-S173.
29. Frøslie K.F., Jahnsen J., Moum B.A., Vatn M.H. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422. IBSEN Group.
30. Baert F., Moortgat L., Van Assche G., Caenepeel P., Vergauwe P., De Vos M., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468.
31. Ha C., Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand?. Curr Gastroenterol Rep 2010, 12:471-478.
32. Loly C., Belaiche J., Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008, 43:948-954.
33. Peyrin-Biroulet L., Loftus E.V., Colombel J.F., Sandborn W.J. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis 2011, 17:471-478.
34. Gryboski J.D., Spiro H.M. Prognosis in children with Crohn's disease. Gastroenterology 1978, 74:807-817.
35. D'Haens G.R. Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol 2010, 7:86-92.
36. Pariente B., Cosnes J., Danese S., Sandborn W.J., Lewin M., Fletcher J.G., et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis 2011, 17:1415-1422.